NIH Precision Medicine Initiative: Implications for Diabetes Research.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27289128.
- Also identified by DOI 10.2337/dc16-0541 and PMC identifier 4915562.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In his January 2015 State of the Union address, President Barack Obama announced a new Precision Medicine Initiative (PMI) to personalize approaches toward improving health and treating disease (www.whitehouse.gov/precision-medicine). He stated that the goal of such an initiative was "to bring us closer to curing diseases like cancer and diabetes, and to give all of us access to the personalized information we need to keep ourselves and our families healthier." Since that time, the National Institutes of Health (NIH) has taken a leadership role in implementing the President's vision related to biomedical research (www.nih.gov/precisionmedicine). Here, we discuss the NIH component of the PMI, related ongoing diabetes research, and near-term research that could position the diabetes field to take full advantage of the opportunities that stem from the PMI.
Medical subject headings
- Biomedical Research
- Diabetes Mellitus
- National Institutes of Health (U.S.)
- Precision Medicine